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ABSTRACT
As new drugs are developed everywhere worldwide to combat many diseases, side effects due to drugs are always a matter of concern. Warfarin is 
indicated for the treatment of venous thromboembolism over many decades and it is always associated with many side effects ranging from bleeding 
complications, gastrointestinal disturbances to skin necrosis. Hair fall with oral anticoagulants had always been a matter of debate and concern and so 
far, only very few case reports have been published on warfarin-induced hair loss. Hence, we report a case of warfarin-induced alopecia in a 39-year-
old male in a tertiary care hospital in Southern India.
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INTRODUCTION
Hair loss also known as alopecia is a very common medical 
condition affecting both sexes due to a wide range of etiological 
factors. Androgenetic alopecia (female/male), alopecia areata, 
telogen effluvium (TE), anagen effluvium, trichotillomania, alopecia 
related conditions such as seborrheic dermatitis, lichen planus and 
discoid lupus erythematosus, tinea capitis, impetigo, secondary 
syphilis, thyroid disease, and iron deficiency are some of well-
known conditions associated with hair loss [1]. Many drugs are 
also implicated in causing hair loss which includes anticoagulants, 
interferon alfa, antidepressants, antitubercular drugs, tyrosine 
kinase inhibitors, and anticancer drugs [2]. Hence, we report a case 
of warfarin-induced alopecia in a 39-year-old patient who underwent 
mechanical heart valve replacement in a tertiary care hospital in 
Southern India.
CASE REPORT
Informed consent was taken from the patient. A 39-year-old female 
patient, known case of mechanical heart valve replacement on warfarin 
therapy since 2008 came with complaints of hair fall. On examination, 
his vitals and blood pressure were stable. On examination, there was 
thinning of hair follicle with associated hair loss. Another system 
examination was normal. There were no other associated causes 
of hair loss in this patient. Hence, the clinician suspected warfarin-
induced hair loss and other drugs causing hair loss were ruled out. 
Hence, diagnosis of warfarin-induced alopecia was made and warfarin 
was not stopped.
DISCUSSION
Warfarin, an oral anticoagulant acts by inhibiting the clotting Factors 
II, VII, IX, and X. It acts by inhibiting the enzyme Vitamin K epoxide 
reductase thereby preventing the gamma carboxylation of clotting 
factors. Gamma carboxylation is required for clotting factors to get 
activated. Warfarin is, therefore, considered as Vitamin K antagonist. 
It is indicated for treatment and prevention of venous thrombosis 
and to prevent thrombotic complication due to atrial fibrillation. 
It is also used to treat patients following prosthetic heart valve 
replacement surgeries, recurrent myocardial infarction and also the 
treatment of transient ischemic attacks. The primary goal of warfarin 
treatment is to maintain the target international normalized 
ratio [3]. Complications of warfarin include nausea, diarrhea, 
vomiting, elevation of liver enzymes, renal nephropathy, skin 
necrosis, purple toe syndrome, bleeding complications, leukopenia, 
and agranulocytosis [4]. Only a few cases have been reported 
worldwide on warfarin-induced alopecia. As per literature search, it 
was found, 14 case reports of warfarin-induced alopecia published 
so far [5]. Hair fall due to the drug is an idiosyncratic adverse 
reaction of unknown mechanism. The first case of warfarin-induced 
alopecia was reported in a 2-year-old girl following ingestion of rat 
poison, which has warfarin as the active ingredient. Hair fall is also 
associated with other oral anticoagulants and as per WHO-Uppsala 
Monitoring Centre VigiBase877 cases of warfarin alopecia had been 
recorded [5].
Mechanism attributed to warfarin-induced hair fall includes antimitotic 
effect on epithelial follicular growth, stimulation of epidermal 
proliferation and inhibition of epithelial bulb cell proliferation. TE is 
strongly suspected as the mechanism due to timing and presentation 
of hair loss induced by warfarin. Another mechanism attributed to 
warfarin-induced hair loss includes change in vasculature of scalp 
leading to focal degeneration of the connective near the blood vessels 
of follicular connective tissue sheath [3,5]. It is also noted that when 
the hair follicles enter the telogen phase asynchronously following 
chronic exposure of drugs, the hair fall becomes clinically significant 
only after months or years of treatment with the offending drug. As per 
previous literature evidence, the alopecia caused by warfarin is usually 
reversible and it reappears on rechallenge. The time range of warfarin-
induced alopecia is from 3 months to 13 years [5]. There are more 
reports with women having alopecia following warfarin compared to 
men. This gender variation is attributed to frequent grooming of hair 
by females which might aggravate the shedding of the resting hair 
resulting from TE [5].
In our case, hair fall was noted in female patient following warfarin 
administration after almost 8 years and other causes were ruled out. 
Hence, a causality assessment was done using Naranjo et al.’s scale [6] 
and a probable causal relationship was ascribed.
CONCLUSION
Since many cases of alopecia due to oral anticoagulants have been 
reported and whether alopecia is dose related is still unclear, proper 
monitoring during anticoagulant therapy is of foremost concern. 
Further, prospective trials can be done to find out the exact incidence 
and prevalence of alopecia due to anticoagulant therapy in Southern 
India.
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